Viriom: Viriom and Chromis publish results of a multi-center open label post-marketing clinical study in 940 COVID-19 patients confirming efficacy of Avifavir at CROI2021
SAN DIEGO, March 9, 2021 /PRNewswire/ -- Viriom Inc., a San Diego CA-based biotech and Chromis, a joint venture of the ChemRar Group and the Russi...
Read full article »
Viriom is a biotech company that develops and commercializes novel therapies for the treatment of life threatening infections such as HIV and HBV.
Read more